Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has al...Show More
competitor of
Metrics
marketSTOCKS
msh_idCOM:CYBIN
localeca
websitehttps://cybin.com/
ipo_date2020-11-10
primary_stock_msh_idNEO:CYBN
source_refe2f43dba-7964-48fb-b77f-c4e83a55c46f
products_or_servicespsychedelic-based therapeutics, drug development
Canada